Search clinical trials for: AFAP1L2-RET

Total 2 results

Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121)

Soft Tissue Sarcoma | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Infantile Fibrosarcoma | Infantile Myofibromatosis

United States, Australia, Japan, Canada, Germany, Korea, Republic of, France, Spain, United Kingdom, Denmark, Italy
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001)

Non-Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Any Solid Tumor

United States, Japan, Taiwan, Australia, Korea, Republic of, Israel, Spain, Switzerland, Singapore, France, Canada, Italy, Germany, United Kingdom, Hong Kong, Denmark

3

Subscribe